Boston Scientific Corporation $BSX is Catalio Capital Management LP’s 3rd Largest Position

Catalio Capital Management LP increased its stake in Boston Scientific Corporation (NYSE:BSX) by 37.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 360,428 shares of the medical equipment provider’s stock after buying an additional 97,456 shares during the quarter. Boston Scientific makes up about 6.4% of Catalio Capital Management LP’s portfolio, making the stock its 3rd largest position. Catalio Capital Management LP’s holdings in Boston Scientific were worth $34,367,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BSX. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter valued at $26,000. Main Street Financial Solutions LLC grew its position in Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC grew its position in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its position in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Leerink Partners reduced their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. BTIG Research restated a “buy” rating and set a $65.00 target price on shares of Boston Scientific in a research report on Tuesday. Barclays reduced their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Finally, The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $85.08.

Boston Scientific Trading Down 4.4%

Shares of BSX stock opened at $44.86 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $55.38 and a two-hundred day moving average price of $73.62. Boston Scientific Corporation has a 12-month low of $44.79 and a 12-month high of $109.50. The firm has a market cap of $66.68 billion, a P/E ratio of 18.77, a price-to-earnings-growth ratio of 0.90 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.